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INTRODUCTION
In the central nervous system (CNS), inflammation is common 
sign of neural diseases such as stroke, Alzheimer’s disease, and 
infection. The regulating and inhibiting neuroinflammation 
are therapeutic targets to cure a variety of CNS diseases [1-
6]. Agmatine (Agm) is an endogenous peptide, synthesized by 
arginine decarboxylase (ADC) that is reported to be present in glia 
and neuronal cells. Agm, a neurotransmitter or neuromodulator, 
is neuroprotective in various models of CNS injury, including 
neurotrauma, neonatal ischemia, and spinal cord injury [7-10]. 
Also, Agm has been reported to attenuate oxidative stress in mouse 
cortical neural stem cells (NSCs) [11]. Agm has been reported 
to protect neurons by reducing the size of ischemic infarctions 
or preventing the loss of neurons after focal or global ischemia 
in vivo. Additionally, Agm protected against neuronal damage 
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Differentiation of neural progenitor cells (NPCs) is important for protecting neural cells and brain tissue during inflammation. 
Interleukin-1 beta (IL-1β) is the most common pro- inflammatory cytokine in brain inflammation, and increased IL-1β levels can 
decrease the proliferation of NPCs. We aimed to investigate whether agmatine (Agm), a primary polyamine that protects neural cells, 
could trigger differentiation of NPCs by activating IL-1β in vitro. The cortex of ICR mouse embryos (E14) was dissociated to culture 
NPCs. NPCs were stimulated by lipopolysaccharide (LPS). After 6 days, protein expression of stem cell markers and differentiation 
signal factors was confirmed by using western blot analysis. Also, immunocytochemistry was used to confirm the cell fate. Agm 
treatment activated NPC differentiation significantly more than in the control group, which was evident by the increased expression 
of a neuronal marker, MAP2, in the LPS-induced, Agm-treated group. Differentiation of LPS-induced, Agm-treated NPCs was 
regulated by the MAPK pathway and is thought to be related to IL-1β activation and decreased expression of TLX, a transcription 
factor that regulates NPC differentiation. Our results reveal that Agm can promote NPC differentiation to neural stem cells by 
modulating IL-1β expression under inflammatory condition, and they suggest that Agm may be a novel therapeutic strategy for 
neuroinflammatory diseases. 
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caused by glucocorticoids and glutamate toxicity in primary 
hippocampal neuron cultures and cell lines [12-15]. Therefore, 
Agm can enhance neurogenesis by regulating ERK1/2 expression 
in subventicular zone NSCs [16]. The phosphatidylinositol 
3-kinase (PI3K)/Akt and extracellular signal-regulated kinase 
(ERK) pathways have been reported to mediate the migration of 
neuroblasts, which enhances brain ischemia-induced neurogenesis 
[17]. PI3K and MEK inhibitors reduce carbachol-induced DNA 
synthesis in progenitor cells [18]. Sung et al. reported that a PI3K 
inhibitor decreases neural progenitors in hypoxic conditions 
[19]. In ischemic brain inflammation, a variety of cytokines and 
chemokines are secreted from damaged brain tissue. Interleukin-1 
beta (IL-1β) is the most common pro-inflammatory cytokine in 
the brain. Previous studies have reported that elevated IL-1β levels 
decrease cell proliferation and neurosphere growth. Also, when 
neural precursors cells (NPCs) were differentiated in the presence 
of IL-1β, there was a significantly lower percentage of new or 
post-mitotic neurons. Also, some studies have demonstrated that 
IL-1β has an anti-proliferative, gliogenic effect on hippocampal 
neuronal differentiation and survival [20-23]. IL-1β signaling 
through the IL-1 receptor type 1 is deleterious to hippocampal 
neurogenesis. Also, the orphan nuclear receptor tailless homolog 
(TLX) has recently been identified to regulate neurogenesis and 
maintain NPCs’ undifferentiated state [24, 25]. Previous studies 
also demonstrated negative relationship between IL-1β and 
TLX in NPCs. These studies indicate that IL-1β reduces NPC 
proliferation and TLX expression in NPCs [23, 26]. Thus, we aimed 
to investigate whether Agm modulates IL-1β and elevated IL-
1β levels regulate TLX expression known as NPC differentiation 
marker in brain inflammation state. This study suggests that Agm 




ICR mice were purchased from Samtako Co. (Kyunggi, Korea). 
Hank’s balanced salt solution (HEPES) was purchased from and 
Gibco BRL stem cell basal medium was obtained from Stem Cell 
Technologies. Fetal bovine (FBS) and horse serum were supplied 
by the Hyclone Company. Agmatine and LPS were obtained 
from the Sigma Chemical Company. Primary antibodies against 
PI3K, phospho-ERK, Cleaved caspase 3, IL-1β, IL-1R1, MAP2, 
SOX2, GFAP, DCX, TLX and β-actin were purchased from Santa 
Cruz Biotechnology, Cell Signaling Biotechnology and Millipore 
Biotechnology. Agmatine was purchased from Sigma Aldrich 
Biotechnology. All the plastic ware was bought from Nunc.
Primary culture
Embryos (E14) were extracted from placental tissue. The cortices 
were aseptically dissected out of the brains and placed in Hank’s 
balanced salt solution (Gibco, USA). The tissues were triturated 
by repeated passage through a fire-polished, constricted Pasteur 
pipette. The dispersed tissues were allowed to settle for 3 min. 
The supernatant was transferred to a fresh tube and centrifuged 
at 1,000 g for 5 min. The pellet was resuspended in NPC basal 
medium with proliferation supplement (Stem Cell Technologies), 
20 ng/ml epidermal growth factor, and fibroblast growth factor 
(Invitrogen). Trypan blue-excluding cells were counted. The cells 
were plated in a 35-mm dish at a density of 0.3×106 cells/ml. The 
cells were cultured for 3 days and then treated as indicated. NPCs 
were used 3 days after treatment [27]. Cultures were maintained in 
a humidified atmosphere of 95% air and 5% CO2 at 37
oC. 
Western blot analysis
Western blots were performed to elucidate the molecular 
mechanism by which Agmatine affects NPC differentiation. 
NPCs from each group cultured for 6 DIV were washed with 
PBS and collected by scraping the neurospheres from the plate. 
The collected NPCs were homogenized in lysis buffer (1% Triton 
X-100, 0.5% NP-40, 150 mM NaCl, 10 mM Tris (Ph 7.4), 1 mM 
Ethylene-diamine tetra acetic acid (EDTA), 1 mM EGTA pH 8.0. 
0.2 Mm sodium orthovandate, 0.2 mM phenylmethylsulfonyl 
fluoride (PMSF), and protease inhibitor cocktail) and centrifuged 
(12,000 rpm at 4oC) for 15 min. Equal amounts of protein (20 μg) 
from the supernatants were separated on 10% acrylamide gels, and 
proteins were electrophoretically transferred onto nitrocellulose 
membranes. The membranes were blocked with Tris-buffered 
saline with Tween-20 and incubated with primary antibody 
overnight. The primary antibodies used were PI3K (1: 2000, 
Millipore, USA), phospho-ERK (1:2000, Millipore, USA), cleaved 
caspase 3 (1:1000, Cell signaling, USA), IL-1β (1:2000, Santa 
Cruz, USA), IL-1R1 (1:2000, Santa Cruz, USA), MAP2 (1:2000, 
Santa Cruz, USA), SOX2 (1:2000, Santa Cruz, USA), GFAP 
(1:2000, Santa Cruz, USA), DCX (1:2000, Santa Cruz, USA), TLX 
(1:2000, Millipore, USA), β-actin (1:1000, Santa Cruz, USA) at 4oC 
overnight. Later the membranes were washed 3 times for 5 mins 
each with TBST. The secondary antibodies were anti-rabbit and 
anti-mouse (1:3000, New England Bio labs, USA) and were used 
for 1 hour at room temperature. After washing with TBST (0.05% 
with Tween 20) 3 times, immunoreactive signals were detected by 
chemiluminescence with an ECL detection system (Amersham 
Life Science, UK) by using the LAS 4000 program. 
270 www.enjournal.org http://dx.doi.org/10.5607/en.2013.22.4.268
Juhyun Song, et al.
Immunocytochemical staining of NPCs
Immunocytochemistry was performed to confirm Agmatine’s 
effect on NPCs. NPCs at 6 DIV were washed 3 times with PBS 
for immunostaining and were blocked for 30 min. After blocking, 
NPCs were incubated with primary antibodies prepared in 
PBS containing 10% FCS and 0.1% Triton X-100, overnight at 
4oC. Primary antibodies used were anti-SOX2 (goat polyclonal, 
1:300), anti-MAP2 (mouse monoclonal, 1:300), anti-GFAP 
(rabbit monoclonal, 1:300). After incubating the NPCs with 
primary antibodies, plates were washed 3 times with PBS for 5 
min and were incubated with secondary antibodies which were 
prepared in PBS containing 10% FCS and 0.1% Triton X-100 
for 1 hour at room temperature. The secondary antibodies used 
were rhodamine rabbit anti-mouse IgG (1:300) and fluorescein 
isothiocyanate mouse anti-rabbit IgG (1:600). NPCs were 
counterstained with DAPI for 10 min at room temperature. 
Immunostained NPCs were visualized using a Carl-Zeiss confocal 
microscope LSM 700 (Carl Zeiss, Germany). 
Statistical analysis
Statistical comparisons were performed by using an independent 
t-test for 2 groups or analysis of variance with the SPSS software. 
Values are expressed as mean±S.E.M of 3-6 experiments. Diffe-
rences were considered significant at #p<0.1, *p<0.05, **p<0.01.
RESULTS
Agmatine promotes ERK signaling under LPS-induced 
inflammation 
To confirm induced signaling pathway induced by Agm under 
mild inflammation, we conducted a western blot analysis. In 
this study, LPS was used at 10 ng/ml and Agm at 100 μM on the 
basis of previous results [28]. Fig. 1A shows that the expression 
of cleaved caspase 3 protein decreased slightly in the Agm-treat 
group compared with that in a control group at the same LPS 
concentration (10 ng/ml). For confirming relatively high caspase 
3 levels in control group, we analyse the expression of protein 
between 0 DIV (at primary culture day) and 6 DIV (our control 
group). Fig. 1B shows that the expression of cleaved caspase 3 did 
not differ between 0 DIV and 6 DIV. As this data, we indirectly 
infer that Agm 100 µM and LPS 10 ng/ml treatment not induces 
severe cell death to NPCs. For checking differentiation of NPCs 
under minor inflammation condition, concentrations of Agm 100 
µM and LPS 10 ng/ml are suitable in this study. Figs. 1A and 1B 
show that 10 ng/ml LPS induced mild inflammation. Figs. 1C and 
1D show that Agm promoted PI3K and ERK signaling compared 
with a control group under treated with LPS. Fig. 1E shows the 
phosphorylation of AKT and also indirectly activity of PI3K in all 
conditions. These data indicate that Agm reduces NPC cell death 
and boosts ERK signaling under inflammation. #p<0.1, *p<0.05, 
**p<0.001.
Agmatine promotes NPC differentiation by regulating IL-
1β under mild inflammatory conditions
To measure the protein expression difference of IL-1β between 
Agm treatment group and control group under LPS induced 
inflammatory condition, we conducted western blot analysis. Fig. 
2A and Fig. 2B show that Agm treatment increases the expression 
level of IL-1β and IL-1R1 relatively compare with control group on 
the same LPS concentration (10 ng/ml). Fig. 2C shows that Agm 
treatment decreases more the expression level of TLX relatively 
than control group. Fig. 2 shows that Agm treatment induces 
increase of IL-1β and IL-1R1 and decrease of TLX in spite of the 
same LPS concentration (10 ng/ml). *p<0.05, **p<0.001.
Agmatine is related to the differentiation of NPCs into both 
neuron and glial cells 
To assess the cell fate in all groups, we conducted immuno-
cytochemistry using Sox2, MAP2, and GFAP antibodies. Fig. 3A, 
B shows that Sox2 expression in neurosphere decreased in the 
LPS only group and in the Agm with LPS group compared to 
that in the normal control group. Fig. 3C shows that the number 
of MAP2-positive cells (neurons) in neurosphere tended to 
increase and the number of GFAP positive cells (astrocytes) in 
neurosphere tended to decrease in the Agm with LPS treated 
group compared with levels in the control group. Fig. 3C indicates 
that neurons tended to increase and astrocytes tended to decrease 
in cells treated with LPS and Agm compare with control cells. Fig. 
3D, E show the quantified MAP2 and GFAP protein levels. These 
data show neuron and astrocyte patterns in all groups. *p<0.05, 
**p<0.001.
DISCUSSION
In the CNS, inflammation is an key sign of neuroinflammatory 
diseases, such as stroke, Alzheimer’s disease, and infection. Thera-
peutic targets for neuroinflammatory diseases include regulating, 
inhibiting, and preventing neuroinflammation [1-6]. Agm, 
a polycationic amine synthesized by the decarboxylation of 
L-arginine, has neuromodulatory and neuroprotective functions in 
the CNS [29, 30]. We previously demonstrated that Agm protects 
neurons and astrocytes against ischemic brain injury [15, 31-33]. 
Agm, as an NMDA receptor blocker, affects calcium homeostasis, 
modulating various functions in the heart, brain, and vasculature 
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[34]. A previous study reported that Agm treatment (100 μM) up-
regulated eNOS expression and maintained functional NO release 
in bEnd3 cells [35]. We also used 100 µM Agm to study its effects 
in the cells without toxicity. Our pilot study showed that 10 ng/
ml LPS induced mild inflammation (cell viability > 65% following 
measured data by MTT assay). Therefore, we used LPS to induce 
mild inflammation and to stimulate IL-1β secretion. Agm has 
been shown to have anti-proliferative effects in the brain and the 
peripheral nervous system [36, 37]. Also, previous research found 
that both ERK1/2 and p38 up-regulate neural differentiation 
of ESCs. Song HW et al. reported that Agm regulates ERK1/2 
activation and this activation may be sufficient to induce the 
differentiation of SVZ NSCs. This report suggests that Agm 
regulates both proliferation and differentiation of specific cell types 
[37]. Carbachol-induced activation of both PI3K/Akt and the 
mitogen-activated protein kinase/ERK kinase (MEK) pathways 
via muscarinic receptors stimulates DNA synthesis in FGF-treated 
neural progenitors isolated from rat cortical neuroepithelium. 
PI3K inhibitors (LY294002 and wortmannin) and a MEK 
inhibitor (PD98059) inhibit carbachol-induced DNA synthesis 
Fig. 1.  Effects of  agmatine mediated by the ERK pathway under LPS-induced 
inflammation. (A) The expression of cleaved caspase 3 protein decreases in the Agm-
treat group compared with the control group under LPS-induced inflammation. (B) 
The expression of cleaved caspase 3 does not differ much between 0 and 6 DIV. (C) The 
expression of PI3K protein increases more in the Agm-only and the Agm- and LPS-treated 
groups than in the LPS-only group. (D) The expression of phospho-ERK increases more 
in the Agm-only and the Agm- and LPS-treat groups than in the LPS-only group. (E)The 
expression of phospho- AKT expression increases more in the Agm-only and the Agm- and 
LPS-treated groups than in the LPS-only group. #p<0.1, *p<0.05, **p<0.001.
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in progenitor cells [18]. Also, Sung et al. reported that PI3K 
inhibitors decreased the neural progenitors in hypoxic conditions. 
The ERK pathway has a central role in differentiation of neural 
progenitor cells [19]. The ERK pathway, which can act in direct 
opposition to JNK and p38 MAP kinases, has also been shown to 
protect against p53-mediated cell death in sympathetic neurons 
[38, 39]. In this study, the PI3K pathway promoted survival of 
the Agm treated group and the Agm with LPS group. These data 
suggest that Agm can induce NPC differentiation by associating 
with TLX to regulate p21 expression in a p53 dependent manner 
in inflammation. In ischemic brain inflammation, a variety of 
cytokines and chemokines are secreted from damaged brain 
tissue. IL-1β is the most common pro-inflammatory cytokine in 
the brain. Previous studies have reported that elevated IL-1β levels 
decrease cell proliferation and neurosphere growth. Also, when 
NPCs were differentiated in the presence of IL-1β, the percentage 
of  new and post-mitotic neurons decreased significantly. 
Also, some studies have demonstrated that IL-1β has an anti-
proliferative, pro-gliogenic effect on hippocampal neuronal 
differentiation and survival [20-22, 40]. Our western blots 
showed increased IL-1β expression in Agm with LPS treated cells 
compared to LPS-treated cells despite an equal LPS concentration 
(10 ng/ml). These data means that the co- treatment of Agm 
(100 µm) and LPS (10 ng/ml) in NPCs could boost the secretion 
of IL-1β known as neuronal differentiation related cytokine. 
In brain inflammation, Agm play a role as a booster to induce 
the secretion of IL-1β for differentiation of NPCs. In addition, 
recent studies have demonstrated that IL-1 type-1 receptor (IL-
1R1) expression is evident in neural progenitors in the DG of the 
hippocampus in adult rats, E18 rat hippocampal neurons, and 
NPCs from E16 rat forebrain, E13.5 mouse cortex, and E21 rat 
hippocampi [21, 41-43] Previous studies indicate that IL-1R1 
is expressed on NSPCs [44, 45]. Therefore, IL-1β expression in 
proliferating and differentiating NPCs can be prevented by IL-
1RA, which prevents IL-1β from binding to IL-1R1 [46]. Other 
research confirmed that IL-1β it binds to cell surface IL-1R1 [47]. 
IL-1R1 expression has been shown to be up-regulated in mature 
hippocampal neurons and astrocytes in the presence of IL-1β [42, 
45]. Our results showed increased IL-1R1 protein expression in 
cells treated with LPS and Agm compared to the LPS-only group. 
Our western blots for checking the expression of IL-1R1 indicate 
that Agm increases IL-1β binding to IL-1R1 and the resultant 
intracellular signaling increases IL-1R1 expression during LPS-
stimulated inflammation. The nuclear receptor TLX has recently 
been identified to regulate adult hippocampal neurogenesis 
[24, 25] and also has a role in hippocampal-dependent learning 
and memory [25]. TLX is an essential regulator of proliferation 
Fig. 2. Effects of agmatine on IL-1β and TLX and subsequent NPC 
differentiation. (A) IL-1β expression increased more in the Agm-only 
and the Agm- and LPS-treated groups than in the LPS-only group. (B) IL-
1R1 expression increased more in the Agm-only and the Agm- and LPS-
treated groups than in the LPS-only group. (C) TLX expression decreased 
more in the Agm- and LPS-treated group than in the other groups. 
*p<0.05, **p<0.001.
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and its deletion leads to non-proliferative NSCs [48]. TLX is 
required to maintain neural stem/progenitor cells (NSPCs) in an 
undifferentiated state and is involved in NSPC fate determination. 
TLX regulates p21 expression in a p53-dependent manner. 
The effects of IL-1β in NSPCs are paralleled by decreased TLX 
expression, and IL-1β expression is related to decreased TLX 
expression [23, 26]. Therefore, Agm promotes ERK signaling, 
and TLX regulates p53-dependent p21 expression. The network 
between the ERK and p53 pathways could explain the correlation 
between Agm and TLX in NPC differentiation. In our study, 
TLX protein expression decreased more in the LPS and Agm 
group than in the control group, similar to previous studies. 
These data indicate that Agm may inhibit IL-1β-induced TLX 
expression in NSPCs. Therefore, SRY-box-containing gene 2 
(Sox2) a transcriptional regulator in NPC differentiation forms a 
molecular network with TLX in adult NSCs. Both Sox2 and TLX 
bind to the upstream region of the Tlx gene. Sox2 binds to the Tlx 
5′ UTR chromatin and activates the Tlx promoter in adult NSCs 
[49]. In this study, Sox2 immunocytochemistry and western blot 
data suggest that Agm may decrease TLX and Sox2 expression 
for inducing differentiation on NPCs in brain inflammation state. 
Previous studies indicate that Agm enhances neurogenesis and 
suppresses astrogenesis by decreasing BMP-2 and -4 and SMAD-
1, -5, and -8 protein expression [27]. Our immunocytochemistry 
data means that Agm increases the differentiation of neurons 
and decreases the differentiation of astrocytes on NPCs in 
LPS-induced inflammation. However, we could not determine 
the exact portion of neurons and glial cells. Increasing IL-
1β expression and decreasing TLX expression induces NPC 
differentiation. Agm could induce NPC differentiation by 
modulating IL-1β in brain inflammation condition. The network 
between ERK signaling activated by Agm and p53 signaling 
activated by TLX could explain the correlation between Agm 
and TLX in NPC differentiation. In conclusion, Agm modulates 
Fig. 3. NPC differentiation mea-
sured by photomicrographs and 
western blot analysis. (A) The 
number of  SOX2-positive cells 
(green) in neurosphere decreased 
more in Agm-only and the Agm- 
and LPS-treated groups than in the 
LPS only group. DAPI was used to 
counterstaining (blue). (B) SOX2 
protein expression decreased more 
than in the LPS-only, in the Agm-
only, the Agm- and LPS-treated 
groups than in the control group. 
(C) The number of MAP2-positive 
cells (red) in neurosphere increased 
in the Agm- and LPS-treated group 
compared to the LPS-only group. 
The number of  GFAP-positive 
cells (green) in neurosphere was 
lower in the Agm-only group than 
in the control group. Scale bar = 
200 μm (×100). (D) MAP2 protein 
expression decreased more in the 
Agm- and LPS-treated group than 
in the LPS-only group. (E) GFAP 
protein expression decreased more 
in the Agm-only and Agm- and 
LPS-treated groups than in the LPS-
only group. *p<0.05, **p< 0.001.
274 www.enjournal.org http://dx.doi.org/10.5607/en.2013.22.4.268
Juhyun Song, et al.
NPC differentiation by regulating IL-1β expression under LPS 
stimulated inflammation condition. Although our data show the 
synergetic effect of Agm and LPS regarding secreting IL-1β, we 
could not suggest the optimal quantitative concentration range of 
IL-1β for differentiation of NPCs. A further study to quantify IL-
1β expression is important to determine a therapeutic strategy of 
Agm for inflammatory brain diseases. This study strongly suggests 
that Agm regulate the differentiation of NPCs by modulating 
differentiation related factors including IL-1β and TLX in spite of 
this limitation. Hence, Agm may be a promising therapeutic agent 
to promote NPC differentiation in neuroinflammatory diseases.
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